Data from Optimer Pharmaceuticals' Prulifloxacin Phase 3 Trial in Traveler's Diarrhea and Strain Typing Data from OPT-80 Study to be Presented at ICAAC/IDSA Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Oct 20, 2008 - Results from three studies related to Optimer Pharmaceuticals, Inc.'s (NASDAQ:OPTR) developmental product candidates will be presented at this year's joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Disease Society of America (IDSA), to be held at the Walter E. Washington Convention Center in Washington, D.C. on October 25-28, 2008.
The presentations and speakers include: -0-
'A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Prulifloxacin as Therapy for Traveler's Diarrhea' Presenter: Herbert L. DuPont, MD Tuesday, October 28 at 10:00am Eastern Time Press Conference (for members of media only) in the Press Conference Room, 143C Press conference will be followed by a poster presentation which is open to all conference attendees: Tuesday, October 28 at 12:15pm-1:15pm Eastern Time Presentation number: L-4134a in Hall C 'Epidemic BI/NAP1 is the Dominant Strain of Clostridium difficile found in Patients in the OPT-80 vs. Vancomycin Clinical Trial in North America and the European Union' Presenter: Adam K. Cheknis Saturday, October 25 at 12:15pm-1:15pm Eastern Time Presentation number: K-508 in Hall C 'SAR Of 11, 12-Carbamate Macrolides/ketolides Linked With 1,4- Substituted- (1,2,3)-triazoles.' Optimer and Cempra Pharmaceuticals will be presenting collaborative data on CEM-101/OP-1068. Presenter: David Pereira Tuesday, October 28 at 11:15am-12:15pm Eastern Time Presentation number: F1-3973 in Hall C There will also be a symposium chaired by Dale N. Gerding, MD, Loyola University Chicago Stritch School of Medicine, Maywood, IL, which is supported by an educational grant from Optimer Pharmaceuticals. 'Clostridium difficile Infections: Current Challenges and Treatments' will address the global and epidemic nature of this potentially fatal disease. Friday, October 24 at 6:00pm-8:00pm Eastern Time Ballroom C of the convention center
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. OPT-80 is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contact
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
or
Invigorate Communications
Mariesa Kemble, 608-850-4745
Posted: October 2008
